Phenytoin sodium (Epdantoin 100 mg) and Rimegepant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
CYP3A induction can reduce rimegepant exposure and migraine-treatment efficacy.
Clinical significance and safety
Phenytoin can lower rimegepant exposure by inducing CYP3A. The rimegepant label advises avoiding strong or moderate CYP3A inducers because treatment may become less effective. A healthcare professional should review the combination; taking extra migraine medicine is not a safe workaround.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.